Epidemiological Survey of Hepatitis D Virus Infection in China
NCT ID: NCT04483518
Last Updated: 2020-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5000 participants
OBSERVATIONAL
2019-06-03
2020-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
NCT05394623
"Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu
NCT03097952
HCV Epidemiological Survey in China Rural Area
NCT04593355
Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
NCT05451082
A Cross-sectional Study for Renal Function of Patients With Chronic Hepatitis B in China
NCT04538651
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Exclusion criteria：Patients who disagree to participate in the trial.
After the informed consent was signed, the quantitative data of the previous surface antigen or HBV DNA titer was collected during the return visit. 4 ml of venous blood was collected on the same day or the remaining serum from the surface antigen or hepatitis B quantitative test was collected for the detection of hepatitis D antibody and/or the quantitative detection of hepatitis D RNA.
After statistical analysis, calculate the hepatitis D infection status in China.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HBV patients
HBV patients with HBsAg positive and/or HBV DNA positive
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
The Fourth Affiliated Hospital of Harbin Medical University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Ruijin Hospital
OTHER
The First Hospital of Jilin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Junqi Niu
Director of the department of Hepatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Junqi Niu, Dr.
Role: STUDY_DIRECTOR
The First Hospital of Jilin University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the first hospital of Jilin University
Changchun, Jilin, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19K056-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.